Acacia Subsidiary Acquires 7 Patent Portfolios With Over 1,900 Patents And Applications Relating To Cardiology And Vascular Device Technology From A Leading Global Medical Device Company
Acacia Research Corporation (Nasdaq: ACTG) announced today that a
subsidiary has acquired 7 patent portfolios with over 1,900 patents and
applications relating to stent grafts, vascular grafts, bypass grafts,
Acacia Research Corporation (Nasdaq: ACTG) announced today that a subsidiary has acquired 7 patent portfolios with over 1,900 patents and applications relating to stent grafts, vascular grafts, bypass grafts, graft retrieval technology, graft manufacturing technology, vena cava filter technology, and filter retrieval technology from a leading global medical device company. “As Acacia’s licensing success in the medical technology sector grows, we are pleased to announce that a leading global medical device company has chosen Acacia as their trusted partner for the licensing of their patented technologies,” commented Paul Ryan, Acacia CEO. “This transaction is one of our largest partnerships to date and is a validation of our growing presence in the medical technology sector. “In addition to our large and growing presence in patent licensing in the technology sector, we are now demonstrating that medical technology will be another major growth driver for Acacia,” commented Ryan. ABOUT ACACIA RESEARCH CORPORATION Acacia Research Corporation’s subsidiaries partner with inventors and patent owners, license the patents to corporate users, and share the revenue. Acacia Research Corporation’s subsidiaries control over 200 patent portfolios, covering technologies used in a wide variety of industries. Information about Acacia Research Corporation and its subsidiaries is available at www.acaciaresearchgroup.com and www.acaciaresearch.com. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995.These statements relating to our growing presence in the medical technology sector and its ability to be a major growth driver for Acacia are based upon our current expectations and speak only as of the date hereof.Our ability to continue expanding our presence in the technology and medical technology sectors, our ability to sustain medical technology as a major growth driver, and our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to source additional intellectual property in the medical technology area and apply our patent licensing expertise to the medical technology market, the ongoing economic slowdown affecting technology companies, theability to successfully develop licensing programs and attract new business, rapid technological change in relevantmarkets, changes in demand for current and future intellectual property rights, legislative, regulatory and competitive developments addressing licensing and enforcement of patents and/or intellectual property in general, and general economic conditions.Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition.We undertake no obligation to revise or update publicly any forward-looking statements for any reason.